Análise do grau de recanalização da trombose venosa profunda: estudo comparativo de pacientes tratados com varfarina versus rivaroxabana

Piati, Polyana Klomfass; Peres, Aline Krampe; Andrade, Danielle Oliveira de; Jorge, Mirela Andressa; Toregeani, Jeferson Freitas

doi:10.1590/1677-5449.180111

Cited by 8 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We mention a study that compared the recanalisation rate in patients treated with warfarin (Group I) and rivaroxaban (Group II) and showed that it was 10%, 52.5% and 78.9% at 30, 90 and 180 days in Group I and 55.3%, 83.5% and 92.4% in Group II respectively (P = 0.041). 18 Discussing the identified RF for VTE, we found that patients with moderate RF had an earlier favourable evolution (from the first month and over 50% at 3 months), probably related to their younger age, and patients with strong RF had the slowest rate of thrombus regression (only 43% at 1 year), probably connected with the later initiation of treatment in less symptomatic patients and with more frequent proximal localisation of DVT.…”

Section: Discussionmentioning

confidence: 81%

Aetiological, clinical and therapeutic prognostic factors for the evolution of deep vein thrombosis followed up with serial venous Doppler ultrasound

Pârv

Tudoran

Parv

et al. 2022

Internal Medicine Journal

View full text Add to dashboard Cite

Background Deep vein thrombosis (DVT) is a dynamic process that can be followed up with Doppler ultrasound (DUS). Aims To evaluate the role of certain factors that can influence the evolution of DVT. Methods In 121 DVT patients (mean age 58.19 ± 14.47 years; 30 with no venous thromboembolism (VTE) identifiable risk factors (RF), 31 with weak RF, 30 with moderate RF and 30 with strong RF), DUS was performed at admission and after 1, 3, 6, 12 and 24 months. Favourable evolution was defined as complete resolution of thrombus, whereas unfavourable evolution was defined as incomplete resolution, thrombosis recurrence or post‐thrombotic syndrome. Results Complete thrombus resolution was found at 1 month (M1) in 24.8% of patients, at 6 months (M6) in 49.6% and at 24 months (M24) in 61.2% of patients. Favourable evolution was seen in younger patients at M1 and M3 (P = 0.004 and P = 0.045) and in cases with earlier treatment (P < 0.0001). In proximal DVT, the risk of non‐favourable evolution was higher (4.05 times at M3, 4.23 times at M6 and 4.29 times at M12). Patients with moderate RF had an earlier favourable evolution (40% at M1, 56.67% at M6 and 70% at M24), and patients with strong RF had the lowest rate of thrombus regression (20% at M1, 36.67% at M6 and 43.33% at M24). Conclusions DVT evolution can last up to 24 months. Older age, strong VTE RF, proximal DVT localisation and late start of therapy constitute unfavourable evolutive prognosis. These cases need closer clinical and DUS monitoring to prevent complications.

show abstract

Section: Discussionmentioning

confidence: 81%

Aetiological, clinical and therapeutic prognostic factors for the evolution of deep vein thrombosis followed up with serial venous Doppler ultrasound

Pârv

Tudoran

Parv

et al. 2022

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…The female sex also appears to be a factor of better recanalization [ 22 ], as well as the absence of comorbidity [ 23 ]. The use of NOAC has been shown to be a better treatment than VKA for venous recanalization after deep LE-VT [ 24 ]. However, this study does not allow us to compare this result.…”

Section: Discussionmentioning

confidence: 99%

Predictive factors of venous recanalization in upper-extremity vein thrombosis

et al. 2021

View full text Add to dashboard Cite

Background Upper extremity venous thrombosis (UEVT) represents about 10% of venous thrombo-embolic disease. This is mainly explained by the increasing use of central venous line, for oncologic or nutritional care. The factors associated with venous recanalization are not known. Objective The aim of this study was to investigate prognosis factor associated with venous recanalization after UEVT. Methods This study included patients with UEVT diagnosed with duplex ultra-sonography (DUS) from January 2015 to December 2017 with DUS evaluations during follow-up. A multivariate Cox proportional-hazards-model analysis was performed to identify predictive factors of UEVT complete recanalization. Results This study included 494 UEVT, 304 proximal UEVT and 190 distal UEVT. The median age was 58 years, 39.5% were women. Clinical context was: hematological malignancy (40.7%), solid cancer (14.2%), infectious or inflammatory context (49.9%) and presence of venous catheters or pacemaker leads in 86.4%. The rate of recanalization without sequelae of UEVT was 38%. For all UEVT, in multivariate analysis, factors associated with complete vein recanalization were: thrombosis associated with central venous catheter (CVC) (HR:2.40, [1.45;3.95], p<0.001), UEVT limited to a venous segment (HR:1.94, [1.26;3.00], p = 0.003), occlusive thrombosis (HR:0.48 [0.34;0.67], p<0.0001), the presence of a PICC Line (HR:2.29, [1.48;3.52], p<0.001), a thrombosis of deep and distal topography (HR:1.70, [1.10;2.63], p = 0.02) or superficial thrombosis of the forearm (HR:2.79, [1.52;5.12], p<0.001). For deep and proximal UEVT, non-occlusive UEVT (HR:2.23, [1.49;3.33], p<0.0001), thrombosis associated with CVC (HR:1.58, [1.01;2.47], p = 0.04) and infectious or inflammatory context (HR:1.63, [1.10;2.41], p = 0.01) were factors associated with complete vein recanalization. Conclusion In this study, factors associated with UEVT recanalization were UEVT limited to a venous segment, thrombosis associated with CVC, a thrombosis of deep and distal thrombosis topography and superficial thrombosis of the forearm. Occlusive thrombosis was associated with the absence of UEVT recanalization.

show abstract

“…This demonstrates not only the efficacy of LMWH in achieving recanalization but also highlights how recanalization is a continuous process that still occurs at 6 and 12 months. In a retrospective analysis, 33 a group of patients receiving UFH and VKA were compared with those on rivaroxaban. Recanalization at 30, 90, and 180 days for the UFH and VKA group was reported at 10%, 52.5%, and 78.9%, respectively.…”

Section: Duration Of Anticoagulationmentioning

confidence: 99%

Anticoagulation Management Post Pulmonary Embolism

Naoum

2024

Methodist DeBakey Cardiovascular Journal

View full text Add to dashboard Cite

Pulmonary embolus (PE) carries a significant impending morbidity and mortality, especially in intermediate and high-risk patients, and the choice of initial anticoagulation that allows for therapeutic adjustment or manipulation is important. The preferred choice of anticoagulation management includes direct oral anticoagulants. Vitamin K antagonists and low-molecular-weight heparin are preferred in special populations or selected patients such as breastfeeding mothers, those with end-stage renal disease, or obese patients, among others. This article reviews the primary and longer-term considerations for anticoagulation management in patients with PE and highlights special patient populations and risk factor considerations.

show abstract

Análise do grau de recanalização da trombose venosa profunda: estudo comparativo de pacientes tratados com varfarina versus rivaroxabana

Cited by 8 publications

References 30 publications

Aetiological, clinical and therapeutic prognostic factors for the evolution of deep vein thrombosis followed up with serial venous Doppler ultrasound

Aetiological, clinical and therapeutic prognostic factors for the evolution of deep vein thrombosis followed up with serial venous Doppler ultrasound

Predictive factors of venous recanalization in upper-extremity vein thrombosis

Anticoagulation Management Post Pulmonary Embolism

Contact Info

Product

Resources

About